AN2 Therapeutics director granted 20,400 stock options

AN2 Therapeutics, Inc. director Stephanie Wong received a grant of stock options covering 20,400 shares on February 20, 2026.

Accepted by SEC EDGAR 02/23/2026 - 04:28 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

AN2 Therapeutics, Inc. director Stephanie Wong received a grant of stock options covering 20,400 shares on February 20, 2026. The options were granted at an exercise price of $0.00 per share and will vest on February 20, 2027, provided she continues to serve through that date.

Insider Trade Summary

Grant/Award: 20,400 shares

Grant/Award 1 txn

Insider Wong Stephanie

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,400	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 20,400 contracts (Direct)

Footnotes (1)

1. F1. The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AN2 Therapeutics (ANTX) report for Stephanie Wong?

AN2 Therapeutics reported that director Stephanie Wong received a grant of stock options for 20,400 shares on February 20, 2026. These options were awarded at an exercise price of $0.00 per share and represent a new equity incentive tied to her ongoing service.

How many AN2 Therapeutics (ANTX) options were granted to Stephanie Wong?

Stephanie Wong was granted stock options covering 20,400 shares of AN2 Therapeutics common stock. This derivative award increases her potential future ownership, subject to vesting conditions, but does not represent an immediate open-market purchase or sale of existing shares.

What is the exercise price of Stephanie Wong’s AN2 Therapeutics (ANTX) stock options?

The stock options granted to Stephanie Wong have an exercise price of $0.00 per share. This means she can acquire the 20,400 underlying shares without paying additional cash, assuming the options vest and are exercised under the award’s terms.

When do Stephanie Wong’s AN2 Therapeutics (ANTX) stock options vest?

The option shares granted to Stephanie Wong vest on February 20, 2027. Vesting is conditioned on her providing continuous service to AN2 Therapeutics through that date, aligning the equity award with her ongoing role as a director of the company.

Is Stephanie Wong’s AN2 Therapeutics (ANTX) option grant a buy or sell transaction?

Stephanie Wong’s transaction is classified as an acquisition by grant or award, not a market buy or sell. She received 20,400 stock options for compensation, with no reported purchase price, and any future share acquisition depends on vesting and exercise.

Does the AN2 Therapeutics (ANTX) Form 4 indicate any share disposals by Stephanie Wong?

The Form 4 does not report any disposals by Stephanie Wong. It shows only an acquisition of 20,400 stock options as a grant or award, with no shares sold, transferred, or otherwise disposed of in the reported transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wong Stephanie

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.04	02/20/2026		A		20,400		(1)	02/19/2036	Common Stock	20,400	$0	20,400	D

Explanation of Responses:

1. The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date.

	/s/ Lucy Day, Attorney-in-Fact for Stephanie Wong	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.